Blood test to predict chemo-immunotherapy response in lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have a type of lung cancer called non-small cell lung cancer (NSCLC) that can be surgically removed.
- Your cancer is at stage IB (tumor at least 4 cm), stage II, or stage IIIB (with involvement of lymph nodes on the same side of the chest).
- You have not had any prior cancer treatment (like chemotherapy, radiation, or immunotherapy) for this cancer.
- Your tumor does not have certain gene changes (EGFR mutations or ALK rearrangement).
- You are generally active and able to care for yourself (performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This study looks at a new blood test to predict how well standard-of-care chemotherapy plus immunotherapy works for people with advanced non-small cell lung cancer. It aims to personalize treatment by identifying patients who may benefit most, potentially improving outcomes and reducing unnecessary side effects.
This study is testing whether certain white blood cells (called neutrophils) in your tumor can predict how well a combination of chemotherapy and immunotherapy works before surgery for lung cancer. If you qualify, you would receive this treatment and then have surgery, and researchers would track your response.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.